Keyword: Neurocrine

Neurocrine is looking to up awareness of movement disorder tardive dyskinesia with its brand-new TV spot.

Execs at this year's J.P. Morgan Healthcare Conference agreed the tone was somewhere between gloom and sunshine.

Last May, Neurocrine’s Ingrezza failed a Tourette syndrome trial, prompting the company to design a new one. But the drug has failed that trial, too.

In the tardive dyskinesia market, doctors initially preferred Neurocrine’s Ingrezza over Teva’s Austedo. But that edge is weakening, one analyst says.

A physician survey suggests new drugs to treat tardive dyskinesia—Neurocrine’s Ingrezza, in particular—may capture sales that beat current expectations.

Downtrodden Teva Wednesday got some good news—and Neurocrine got some company.

Neurocrine’s Ingrezza, fresh off its first FDA approval and aiming for another, just hit a major roadblock.

Neurocrine is out with its price for Ingrezza—and it’s even higher than some industry watchers expected.

Take a look at this year’s new drug approval announcements, and you may notice a pattern emerging.

The tardive dyskinesia market race is officially on—and it’s Neurocrine that has the go-ahead to kick things off.